The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved
Open accessAbstract
It is not uncommon for new anti-cancer drugs or therapies to show highly effective, and sometimes even spectacular anti-cancer treatment results using transplantable tumors in mice. These models frequently involve human tumor xenografts grown subcutaneously in immune deficient hosts such as athymic (nude) or severe combined immune deficient (SCID) mice. Unfortunately, such preclinical results are often followed by failure of the drug/therapy in clinical trials, or, if the drug is successful, it usually has only modest efficacy results, by comparison. Not surprisingly, this has provoked considerable skepticism about the value of using such preclinical models for early stage in vivo preclinical drug testing. As a result, a shift has occurred towards developing and using spontaneous mouse tumors arising in transgenic and/or knockout mice engineered to recapitulate various genetic alterations thought to be causative of specific types of respective human cancers. Alternatively, the opinion has been expressed of the need to refine and improve the human tumor xenograft models, e.g., by use of orthotopic transplantation and therefore promotion of metastatic spread of the resultant "primary" tumors. Close inspection of retrospective and prospective studies in the literature, however, reveals that human tumor xenografts-even non metastatic ectopic/subcutaneous "primary" tumor transplants-can be remarkably predictive of cytotoxic chemotherapeutic drugs that have activity in humans, when the drugs are tested in mice using pharmacokinetically clinically equivalent or "rational" drug doses. What may be at variance with clinical activity, however, is the magnitude of the benefit observed in mice, both in terms of the degree of tumor responses and overall survival. It is argued that this disparity can be significantly minimized by use of orthotopic transplant/metastatic tumor models in which treatment is initiated after the primary tumor has been removed and the distant metastases are well established and macroscopic-i.e., the bar is raised and treatment is undertaken on advanced, high volume, metastatic disease. In such circumstances, survival should be used as an endpoint; changes in tumor burden using surrogate markers or micro-imaging techniques can be used as well to monitor effects of therapies on tumor response. Adoption of such procedures would more accurately recapitulate the phase I/II/III clinical trial situation in which treatment is initiated on patients with advanced, high-volume metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationLess is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Fidler, I. J. (1986) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00049529 · Cited by 373
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 369
Self-citationCancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Self-citationTransplantation of Human Tumors in Nude Mice23
Shimosato, Y., Kameya, T., Nagai, K., Hirohashi, S., Koide, T., Hayashi, H., & Nomura, T. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/56.6.1251 · Cited by 264
Metronomic scheduling: the future of chemotherapy?
Gasparini, G. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00587-3 · Cited by 251
Klement, G. L., Huang, P. H., Mayer, B., Green, S. K., Man, S., Böhlen, P., Hicklin, D. J., & Kerbel, R. S. (2002) · PubMed · Cited by 243
Self-citationEder, J. P., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.082 · Cited by 243
Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models
Hoffman, R. M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00848-3 · Cited by 240
Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1815 · Cited by 235
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello, L., Carrabba, G. G., Giussani, C. G., Lucini, V., Cerutti, F., Scaglione, F., Landré, J., Pluderi, M., Tomei, G., Villani, R. M., et al. (2001) · PubMed · Cited by 180
Further evidence to support the melanocytic origin of MDA-MB-435
Ellison, G. (2002) · Molecular Pathology · doi:10.1136/mp.55.5.294 · Cited by 164
Zamboni, W. C., Stewart, C. F., Houghton, P. J., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.7.505 · Cited by 136
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson, J., Zamboni, W. C., Cheshire, P. J., et al. (1997) · PubMed · Cited by 125
Chemotherapeutic drugs—more really is not better
Fidler, I. J., & Ellis, L. M. (2000) · Nature Medicine · doi:10.1038/74969 · Cited by 117
Horowitz, M. E., Etcubanas, E., Christensen, M. L., et al. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.308 · Cited by 111
High-Time Chemotherapy or High Time for Low Dose
Kamen, B. A., Rubin, E., Aisner, J., & GLATSTEIN, E. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2935 · Cited by 104
What is the Optimal Rodent Model for Anti-tumor Drug Testing?
Kerbel, R. S. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006152915959 · Cited by 76
Self-citationHoffman, R. M. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006188412324 · Cited by 70
Testing of new agents in childhood cancer preclinical models: meeting summary.
Houghton, P. J., Adamson, P. C., Blaney, S. M., Fine, H. A., Gorlick, R. G., Haber, M., Helman, L. J., Hirschfeld, S., Hollingshead, M. G., Israel, M. A., et al. (2002) · PubMed · Cited by 61
Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y., & Nomura, T. (1989) · Cancer · Cited by 60
Efficacy of oral irinotecan against neuroblastoma xenografts
Thompson, J., Zamboni, W. C., Cheshire, P. J., et al. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199704000-00002 · Cited by 54
Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin
Shih, I., Torrance, C. J., Sokoll, L. J., Chan, D. W., Kinzler, K. W., & Vogelstein, B. (2000) · Nature Medicine · doi:10.1038/76299 · Cited by 44
Why drugs fail: of mice and men revisited.
Takimoto, C. H. M. (2001) · PubMed · Cited by 42
Why Transgenic and Knockout Animal Models should be used (for Drug Efficacy Studies in Cancer)
Rosenberg, M. P., & Bortner, D. M. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006196614142 · Cited by 35
Jackson‐Grusby, L. (2002) · Oncogene · doi:10.1038/sj.onc.1205603 · Cited by 35
Inaba, M., Tashiro, T., Kobayashi, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y., & Nomura, T. (1988) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1988.tb01621.x · Cited by 27
Cited by
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3281 · Cited by 694
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060929 · Cited by 468
Metadata
- Authors
- Kerbel, R. S.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2003-03
- Volume
- 2
- Issue
- sup1
- Pages
- 133-138
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2120191503
- Cited by
- 326
- References
- 33
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.